The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure(ELIVE pre-HF Study)
- Conditions
- Pre-Heart Failure (Non-diabetic)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2024-512062-34-00
- Lead Sponsor
- niversity College Dublin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Aged >40 years old with at least one cardiovascular risk factor(s) including: a. Hypertension b. Coronary artery disease c. Obesity d. Previous ischaemic stroke or TIA e. Peripheral vascular disease f. Hypercholesterolaemia g. Previous chemotherapy or radiotherapy to the chest, Not currently on SGLT-2i treatment, LAVI =29mL/m2 obtained by Doppler echocardiography, Are able and agree to Fitbit use and exercise prescription, Subjects must be able and willing to give written informed consent, Access to a smart phone, Non-diabetic
Aged >85years old, Presence of haemodynamically significant mitral and /or aortic valve disease, Conditions that are expected to compromise survival over the study period, Concomitant participation in other interventional clinical trials, Subjects with contraindications to MRI or allergic reactions to MRI contrast dye (Dotarem), Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drugs., Women who are pregnant, breast-feeding, or women of childbearing potential not using estro-progestative oral or intra-uterine contraception or implants, or women using estro-progestative oral or intra-uterine contraception or implants but who consider stopping it during the planned duration of the study. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. (Contraception must be continued for one week following discontinuation of study drug), Refusal to provide informed consent, Unable to exercise due to concomitant medical condition, such as severe arthritis, uncontrolled pain, severe airways disease or falls risk., Cognitive impairment, Systolic blood pressure <100mmHg, Subjects with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, Recent (within 3 months) acute myocardial infarction or stroke, Permanent or persistent Atrial Fibrillation, Any diabetes mellitus, Contraindication to SGLT-2i, Renal insufficiency with eGFR <20mL per min per 1.73m2 . For those patients randomised to the substudy CMR with gadolinium, the eGFR cut off will be <30mL per min per 1.73m2 ., A history of HF, Asymptomatic left ventricular systolic dysfunction as defined as LVEF <50% on most recent measurement.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To assess the impact of Empagliflozin on diastolic dysfunction measured by LAVImax over 6 months in non-diabetic, pre-HFPEF patients using CMR;Secondary Objective: To assess the effect of Empagliflozin versus usual medical care on CMR left ventricular structure and function, To assess the effect of Empagliflozin on Brain Natriuretic Peptide and eGFR;Primary end point(s): Change in LAVImax measured by CMR over 6 months
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Change in CMR LVMI between baseline and 6 months;Secondary end point(s):Change in CMR LVESVi between baseline and 6 months;Secondary end point(s):Change in CMR LVEDVi between baseline and 6 months;Secondary end point(s):Change in CMR LVEF between baseline and 6 months.;Secondary end point(s):Change in CMR e’ between baseline and 6 months.;Secondary end point(s):Change in CMR LV myocardial strain (measured using feature tracking) between baseline and 6 months.;Secondary end point(s):Change in CMR parameter LA myocardial strain (measured using feature tracking) between baseline and 6 months;Secondary end point(s):Change in serum BNP and eGFR from baseline to 6 months